Irvine, CA (Feb 7, 2022) - Rubicon Biotechnology LLC is pleased to announce a grant award from the US Army Medical Research & Development Command (USAMRDC) to study Rubicon’s Rapid Recovery technology in cochlear cytoprotection. The project, titled “Rapid Delivery of Heat Shock Protein 72 for Auditory Cytoprotection After a Blast Exposure” is supported by…
Read more
Rubicon Awarded Ocular Cytoprotection Grant from USAMRDC
Irvine, CA (June 14, 2021) - Rubicon Biotechnology LLC is pleased to announce a grant award from the US Army Medical Research & Development Command (USAMRDC) to study Rubicon’s Rapid Recovery technology in ocular cytoprotection. The project, titled “Rapid Delivery of Hsp72 for Ocular Cytoprotection After a Traumatic Brain Injury” is supported by the Assistant…
Read more
Rubicon Awarded Traumatic Brain Injury Grant from USAMRDC
Irvine, CA (May 7, 2021) - Rubicon Biotechnology LLC is pleased to announce an award from the US Army Medical Research & Development Command (USAMRDC) to study Rubicon’s Rapid Recovery technology in traumatic brain injury (TBI). The 3-year study titled, "Intracellular Delivery of Hsp72 for Neural Cytoprotection After Traumatic Brain Injury”, includes the optimization and…
Read more
Rubicon Announces National Eye Institute Grant
Lake Forest, CA (October 27, 2017) - Rubicon Biotechnology, LLC is pleased to announce that it was awarded a SBIR Phase I grant by the National Eye Institute titled “Targeted Hsp72 as a Therapeutic for Central Retinal Artery Occlusion”. Rubicon is collaborating with Drs. Michael Gorin and Anna Matynia and their teams at the Stein…
Read more
- 1
- 2